US20060172017A1 - Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces - Google Patents

Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces Download PDF

Info

Publication number
US20060172017A1
US20060172017A1 US11/340,410 US34041006A US2006172017A1 US 20060172017 A1 US20060172017 A1 US 20060172017A1 US 34041006 A US34041006 A US 34041006A US 2006172017 A1 US2006172017 A1 US 2006172017A1
Authority
US
United States
Prior art keywords
method
gas
capnic
carbon dioxide
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/340,410
Inventor
Julia Rasor
Ned Rasor
Gerard Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capnia Inc
Original Assignee
Capnia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16412599P priority Critical
Priority to US18549500P priority
Priority to US09/708,186 priority patent/US6959708B1/en
Priority to US11/192,852 priority patent/US20060076011A1/en
Application filed by Capnia Inc filed Critical Capnia Inc
Priority to US11/340,410 priority patent/US20060172017A1/en
Assigned to CAPNIA, INCORPORATED reassignment CAPNIA, INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RASOR, JULIA S., RASOR, NED S., PEREIRA, GERARD F.
Publication of US20060172017A1 publication Critical patent/US20060172017A1/en
Assigned to CAPNIA, INC. reassignment CAPNIA, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME AND TO UPDATE THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 017445 FRAME 0036. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE NAME IS CAPNIA, INC. AND THE ASSIGNEE ADDRESS IS 2445 FABER PLACE, SUITE 250, PALO ALTO, CA 94303. Assignors: RASOR, JULIA S., RASOR, NED S., PEREIRA, GERARD F.
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H33/00Bathing devices for special therapeutic or hygienic purposes
    • A61H33/14Devices for gas baths with ozone, hydrogen, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033Details of the piercing or cutting means
    • A61M15/0041Details of the piercing or cutting means with movable piercing or cutting means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/009Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H33/00Bathing devices for special therapeutic or hygienic purposes
    • A61H33/14Devices for gas baths with ozone, hydrogen, or the like
    • A61H2033/145Devices for gas baths with ozone, hydrogen, or the like with CO2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • A61M15/0068Indicating or counting the number of dispensed doses or of remaining doses
    • A61M15/0083Timers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/02Gases
    • A61M2202/0225Carbon oxides, e.g. Carbon dioxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder

Abstract

Apparatus and methods deliver vasoconstrictive agents simultaneously with capnic gases. The capnic gases can enhance the effectiveness of the vasoconstrictive agent, lower the dosage of drug or concentration of agent necessary to achieve a therapeutic result, or both. Exemplary capnic gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • This application is a continuation-in-part of U.S. application Ser. No. 11/192852 (Attorney Docket No. 020017-000320US), filed Jul. 29, 2005, which was a continuation-in-part of U.S. application Ser. No. 09/708,186 (Attorney Docket No. 020017-000310US), filed Nov. 7, 2000 (now U.S. Pat. No. 6,959,708), which claimed the benefit of U.S. Provisional Patent Application Nos. 60/164,125, filed on Nov. 8, 1999 and 60/185,495, filed on Feb. 28, 2000, each of which is incorporated by reference herein.
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to drug delivery. More particularly, the present invention relates to methods and apparatus for delivering agents that cause vasoconstriction to mucosal and other tissue surfaces in the presence of capnic gases, particularly for the treatment of migraine headaches.
  • Drug delivery to mucosal surfaces, such as the mucosa of the nose, is well known. While in some cases drugs delivered to the nose and other mucosal surfaces are intended to have local effect, more often such transmucosal drug delivery is intended for systemic administration. In either case, penetration of the drug into or through the mucosa is limited by the ability of the particular drug to pass into or through the mucosal cell structure. Such resistance from the mucosal cell structure can result in slowing of the delivery, the need to use higher dosages of the drug, or in the case of larger molecules, the inability to deliver via a nasal or other mucosal route.
  • Migraine headaches are a form of severe headache that tends to recur in susceptible patients. Migraine headaches may be accompanied by associated symptoms, such as nausea, vomiting, hypersensitivity to light, sound and odor. Patients suffering from migraines often must remain immobile since even small movements can exacerbate the pain. In “classic” migraine etiology, the patient often experiences an aura some ten to thirty minutes before the onset of the migraine. The aura may include a perception of flashing lights, zigzag lines, or in some instances may even cause temporary vision impairment. So-called “common” migraines are not preceded by such an aura. Both types of migraines may occur as often as several times a week or as rarely as once every few years.
  • Migraines are most often treated using drugs that cause vasoconstriction. For years, ergotamines was the primary drug available for treating severe migraine pain. More recently, triptan drugs have become available for treating all forms of migraine.
  • While drug therapy using triptans and ergotamines are often effective, the drugs can require one to two hours to reach effective plasma concentrations. Even so-called quick acting forms, such as quick-melt tablets, intra-nasal sprays, injectable forms of the drugs, and topical forms of the drug, still have significant lag times before they become effective. Moreover, not all individuals benefit from triptans, ergotamines, or other drug therapies for migraines.
  • Very recently, the use of carbon dioxide and other capnic gases alone and in combination with other gases has been proposed for the treatment of migraine headaches and other conditions. The carbon dioxide is preferably delivered to nasal or other mucosa without inhalation. It is believed that the carbon dioxide may cause an acidosis which inhibits the release of calcitonin gene-related peptide (CGRP) which in turn reduces the pain and associated symptoms resulting from the migraine. It has also been found that the onset of relief is usually much more rapid than that achieved with triptans, ergotamines, and other systemic drug therapies.
  • Despite the promise of conventional drug therapies and the newer delivery of capnic gases, neither therapy is effective in all individuals and neither therapy is entirely effective in relieving all migraine pain and associated symptoms in all circumstances. It would thus be desirable to provide improved methods and systems for treating migraine headaches. In particular, it would be desirable to provide treatments which are more effective, more rapid, more long-lasting, and/or which have other benefits when compared to the administration of either known systemic drugs or capnic gases alone.
  • 2. Description of Background Art
  • Inhalation devices, systems and methods for delivering carbon dioxide and other gases and aerosols to patients, with and without co-delivery of a drug are described in U.S. Pat. Nos. 3,776,227; 3,513,843; 3,974,830; 4,137,914; 4,554,916; 5,262,180; 5,485,827; 5,570,683, 6,581,539; and 6,652,479. While some methods and devices provide for co-delivery of a drug and carbon dioxide or other gases, the purpose is usually not potentiation. For example, carbon dioxide may be used as a safe propellant, as shown in Wetterlin, U.S. Pat. No. 4,137,914. See also copending applications Ser. No. 09/614,389 (Attorney Docket No. 020017-000110US); Ser. No. 10/666,947 (Attorney Docket No. 020017-000420US); and Ser. No. 10/666,562 (Attorney Docket No. 020017-000430US), the full disclosures of which are incorporated herein by reference.
  • Additional background art may be found in the following references: Guyton A C, Hall J E. Textbook of Medical Physiology. Ninth Ed., W.B. Saunders Co., Philadelphia, 1996; Tang A, Rayner M, Nadel J. “Effect of CO2 on serotonin-induced contraction of isolated smooth muscle,” Clin Research 20:243, 1972; Qi S, Yang Z, He B. “An experimental study of reversed pulmonary hypertension with inhaled nitric oxide on smoke inhalation injury,” Chung Hua Wai Ko Tsa Chih 35(1):56-8, January 1997; Loh E, Lankford E B, Polidori D J, Doering-Lubit E B, Hanson C W, Acker M A. “Cardiovascular effects of inhaled nitric oxide in a canine model of cardiomyopathy,” Ann Thorac Surg 67(5): 13 80-5, May 1999; Pagano D, Townend J N, Horton R, Smith C, Clutton-Brock T, Bonser R S. “A comparison of inhaled nitric oxide with intravenous vasodilators in the assessment of pulmonary haemodynamics prior to cardiac transplantation,” Eur J Cardiothorac Surg 10(12): 1120-6, 1996; and Sterling G, et al. “Effect of CO2 and pH on bronchoconstriction caused by serotonin vs. acetylcholine,” J of Appl Physiology, vol. 22, 1972.
  • BRIEF SUMMARY OF THE INVENTION
  • The present invention provides methods and apparatus for treating patients, particularly patients suffering or at risk of suffering from migraine headaches, by administering a vasoconstrictive agent to the patient and simultaneously delivering a capnic gas to a nasal, oral, auricular, or ocular membrane of the patient. By “simultaneously,” it is meant that the vasoconstrictive agent will be administered and the capnic delivered at the same time or within a very short time of each other, typically within 60 minutes, preferably within 30 minutes, and more preferably within 10 minutes. In some instances, it may be desirable to deliver the vasoconstrictive agent together with the capnic gas, e.g., where the capnic gas can act as a carrier for the vasoconstrictive agent. It will be more common to deliver the vasoconstrictive agent separately in a separate dosage form, such as any of the dosage forms which are commonly available for the particular vasoconstrictive agents described below.
  • In preferred protocols, at the onset of a migraine headache, the patient would take a dose of the vasoconstrictive agent and substantially simultaneously initiate delivery of the capnic gas to the target membrane. The capnic gas would provide a rapid onset of action, possibly by inhibiting the release of CGRP as described above, in order to interrupt or delay progression of the migraine episode. At the same time, the circulating plasma levels of the vasoconstrictive agent would increase, resulting in constriction of the cranial blood vessels. The patient would experience a more effective treatment in one of several ways. As the capnic gas would at least slow the progression of the migraine, the migraine would be less intense at the time effective plasma levels of the vasoconstrictive agent have been achieved. The magnitude of pain and associated symptoms experienced by the patient should be lessened at all points during the treatment. In other cases, the patient might benefit by reducing the dosage of the vasoconstrictive agent and thereby reducing side effects.
  • Exemplary vasoconstrictive agents useful in the methods of the present invention include both triptans and ergotamines. The use of triptans is preferred, and common triptans include sumatriptan, zolmitriptan, rizatriptan, almotriptan, naratriptan, eletriptan, and frovatriptan. Common ergotamines include ergotamine tartrate (Cafergot®, Wigraine®, Ergostat®), and dihydroergotamine DHE-45 (Migranal®).
  • In addition to vasoconstrictive agents, in some instances, the methods of the present invention could combine the delivery of capnic gases with other known treatments for migraines, including certain anticonvulsants, such as carbamazepine and topiramate.
  • The vasoconstrictive agents will be delivered systemically, and may be delivered in any conventional systemic form, including oral dosage forms (tablets, gels, capsules, and the like), intranasal forms (in which case they could optionally be combined with delivery of the capnic gases), forms intended for pulmonary delivery, injectable forms, and topical forms (for transcutaneous delivery). In particular for the delivery of triptans, presently available dosage forms include tablets, orally dissolving tablets (also known as quick-melts or rapi-melts), intranasal sprays, and subcutaneous injection.
  • Preferred capnic treatment gases include carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases, such as dilute hydrochloric acid and the like. Particularly preferred are carbon dioxide gases having a relatively high concentration, typically greater than 10% by volume, usually greater than 20% by volume, and preferably greater than 25% by volume and often being as great as 80% by volume, 90% by volume, and in many instances being substantially pure. The capnic gases may be used in combinations of one or more adjuvant gases and/or may be combined with physiologically inert gases such as nitrogen, to control concentration of the capnic gases.
  • The capnic gas is delivered to a nasal, oral, auricular, or ocular membrane of the patient, typically using a hand-held or other dispenser. Preferably, the capnic gas will be delivered to a nasal or oral mucosa, while the patient refrains from inhaling the capnic gas. In the exemplary embodiments, the capnic gas is infused through a nostril and exits through a nostril and/or the mouth. The patient will refrain from inhaling, typically by holding the velum in the throat closed, while the capnic gas is infused. In other instances, the capnic gas will be infused through the mouth and be allowed to exit through at least one nostril, usually both nostrils. In those instances, the patient will also refrain from inhaling the gas.
  • The capnic gases will usually be delivered using a dispenser. Typically, the dispenser includes a pressurized source of the capnic gas and a valve assembly for releasing the gas at a controlled flow rate, typically in the range from 0.5 cc/sec to 30 cc/sec in the case of high concentration of carbon dioxide. Optionally, the vasoconstrictive agent may be dissolved or suspended in the pressurized capnic gas for simultaneous delivery. Alternatively, the vasoconstrictive agent may be delivered simultaneously from a separate receptacle, either through the same or a different delivery path. Often, the capnic gas and the vasoconstrictive agent, even when stored in separate receptacles, will be delivered through a common conduit and nozzle to allow for both simultaneous and sequential delivery.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 illustrates an exemplary capnic gas infusion device, illustrating a charge/dose and dose rate adjustment features.
  • FIG. 2 is a schematic illustration of a delivery system incorporating separate receptacles for the capnic and the physiologically active agent, where the receptacles are joined through valves into a common delivery conduit.
  • FIGS. 3A-3E show application of the capnic gas optionally in combination with the physiologically active agent to the nose, mouth, both nostrils, eye, and ear, using a gas dispenser according to the present invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • An exemplary carbon dioxide dispenser 100 comprising a carbon dioxide cartridge 101 is illustrated in FIG. 1. The embodiment of FIG. 1 is described in greater detail in parent application Ser. No. 09/708,186, now U.S. Pat. No. 6,959,708, the full disclosure of which has previously been incorporated herein by reference. A user delivers a dose of carbon dioxide or other treatment gas, referred to generally as “capnic gases” (optionally carrying the vasoconstrictive agent to be delivered) by applying the top of the dispenser 608 to the user's nose or mouth and pushing a button 600 which releases an internal mechanism to allow the CO2 to flow from the top of the dispenser 608. The internal mechanism will lower the pressure of CO2 in the cartridge and will control the flow rate within suitable ranges, typically from 0.5 to 30 cc/sec. The flow rate may be maintained for a suitable time period, typically at least 2 seconds when suffusing the nasal and sinus passages. The device is cocked by rotation as shown by arrow 602 and pushing the button 600 to deliver the dose by an automatic counter-rotation. The user may select the specific carbon dioxide flow rate by setting at a set screw through aperture 609.
  • The dispenser 100 of FIG. 1 may be used to deliver any of the capnic gases in accordance with the principles of the present invention. The capnic gases may be delivered with or without the vasoconstrictive agent incorporated in the canister 101. In cases where the capnic gas is to be delivered by itself, at some suitable concentration, the vasoconstrictive agent will have to be delivered systemically in some other manner. The vasoconstrictive agent could be delivered in any of the conventional dosage forms described above or could be delivered to the target mucosa by suffusion or infusion, by placing a liquid, powder, or the like over the tissue surface, by introducing a vapor, mist, or the like using conventional drug delivery vapor sources and misters, or the like.
  • FIG. 2 is a schematic illustration showing a system for simultaneous or closely separated sequential delivery of the capnic gas and vasoconstrictive agent. The capnic gas is held in a separate cartridge or other container 202 while the vasoconstrictive agent is held in a cartridge or other container 204. Both the gas and the vasoconstrictive agent will be in a gaseous, vapor, mist, or other flowable form which permits them to pass through associated valves 206 and 208 respectively, and thereafter through a conduit 210 which receives flow from both valves. The valves will be suitable for controlling both flow rate and pressure of the capnic gas and the vasoconstrictive agent. It will be appreciated that more complex delivery systems can be provided including flow rate measurement, feedback control, temperature control, timers, and the like.
  • Referring now to FIGS. 3A to 3E, a variety of ways for effecting mucosal infusion with the capnic gas, optionally combined with the vasoconstrictive agent, are illustrated. The capnic gas is preferably infused at a flow rate in a range from 0.5 cc/sec to 30 cc/sec, depending on the tolerance of the individual being treated. In some instances, the selected drug or other vasoconstrictive agent can be delivered separately by suffusion, infusion, misting, the application of powder, or the like. As shown in FIGS. 3A-B, the individual P infuses oral and nasal mucous membranes by placing the source of low flow rate CO2 (or other mixed gas) or other appropriately physiologically active gas or vapor in or around a facial orifice, such as the mouth or nostril, while substantially inhibiting the flow of the CO2 into the trachea and lungs by limiting inhalation of the CO2. If the mouth is infused the gas is allowed to exit from the nostrils. Alternatively, one or both nostrils may be infused either by using the dispenser head shown in FIG. 3B or by use of a cup or similar device that covers both nostrils as shown in FIG. 3E. The gas is allowed to flow from a remaining open orifice, i.e., either the mouth, the uninfused nostril, or both as appropriate. Completely holding the breath is not necessary to substantially prevent inhalation of the CO2. With practice, it is possible for the individual to breathe through an uninfused orifice. For example, if one nostril is infused and the gas is allowed to exit though the other nostril, it is possible for the individual to breathe through the mouth without substantial inhalation of the infused gas. The eye or eyes may also be infused using a cup as shown in FIG. 3C or merely by holding a hand over the eye and releasing the gas between the hand and the eye. Persons of ordinary skill in the art will appreciate that a double cup could be developed to infuse both eyes simultaneously, and similarly appropriate heads could be developed to infuse the mouth and one nostril. The ear or ears may also be infused as shown in FIG. 3D. Note that a similar process may be used with the first embodiment to infuse a mixture of a drug and gas into various facial orifices.
  • Infusion can be continued to the limit of tolerance or until the desired potentiation effect is realized. Since most individuals develop a temporary increased tolerance after extended applications or repeated applications, it may be possible and desirable to increase the duration of additional infusions after a few applications when all applications occur within a short time of each other, i.e., approximately 1 to 20 minutes between each application.
  • While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.

Claims (24)

1. A method for treating a patient, said method comprising:
administering a vasoconstrictive agent to the patient; and
delivering a capnic gas to a nasal, oral, auricular, or ocular membrane of the patient;
wherein the vasoconstrictive agent and capnic gas are administered and delivered simultaneously.
2. A method as in claim 1, wherein the vasoconstrictive agent comprises a triptan.
3. A method as in claim 1, wherein the vasoconstrictive agent comprises an ergotamine.
4. A method as in claim 1, wherein the capnic gas is delivered to a nasal or oral mucosa while the patient refrains from inhaling the capnic gas.
5. A method as in claim 4, wherein the capnic gas is infused through a nostril and exits through a nostril and/or the mouth.
6. A method as in claim 4, wherein the capnic gas is infused through the mouth and exits through at least one nostril.
7. A method as in any one of claims 4 to 6, wherein the capnic gas comprises carbon dioxide at a concentration of at least 50% by volume and is delivered at a controlled flow rate in the range from 0.5 cc/sec to 30 cc/sec.
8. A method as in claim 1, wherein the gas is selected from the group consisting of carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.
9. A method as in claim 8, wherein the gas comprises carbon dioxide.
10. A method as in claim 9, wherein the carbon dioxide is present at a concentration of at least 50% by volume.
11. A method as in claim 10, wherein the carbon dioxide is substantially pure.
12. A method for treating a patient for a migraine headache, said method comprising:
administering a systemic migraine medication to the patient; and
delivering a capnic gas to a nasal, oral, auricular, or optical membrane of the patient;
wherein the migraine medication and the capnic gas are administered and delivered within ______ minutes of each other.
13. A method as in claim 12, wherein the migraine medication is selected from the group consisting of a 5-HT ligand, an alpha-adrenergic ligand, an anticonvulsant, a tricyclic antidepressant, a selective serotonin reuptake inhibitor, a monoamine oxidase (MAO) inhibitor, a calcium channel blocker, lithium carbonate, a corticosteroid, and a nasal decongestant.
14. A method as in claim 12, wherein the migraine medication is a vasoconstrictive agent.
15. A method as in claim 14, wherein the vasoconstrictive agent comprises a triptan or an ergotamine.
16. A method as in claim 12, wherein the capnic gas is delivered to a nasal or oral mucosa while the patient refrains from inhaling the capnic gas.
17. A method as in claim 16, wherein the capnic gas is infused through a nostril and exits through a nostril and/or the mouth.
18. A method as in claim 16, wherein the capnic gas is infused through the mouth and exits through at least one nostril.
19. A method as in any one of claims 16 to 18, wherein the capnic gas comprises carbon dioxide at a concentration of at least 50% by volume and is delivered at a controlled flow rate in the range from 0.5 cc/sec to 30 cc/sec.
20. A method as in claim 12, wherein the capnic gas is selected from the group consisting of carbon dioxide, nitric oxide, nitrous oxide, and dilute acid gases.
21. A method as in claim 20, wherein the gas comprises carbon dioxide.
22. A method as in claim 21, wherein the carbon dioxide is present at a concentration of at least 50% by volume.
23. A method as in claim 22, wherein the carbon dioxide is substantially pure.
24. A method for treating a patient suffering from a migraine condition, said method comprising:
constricting cranial blood vessels; and
substantially simultaneously inhibiting the release of calcitonin gene-related peptide (CGRP).
US11/340,410 1999-11-08 2006-01-25 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces Abandoned US20060172017A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US16412599P true 1999-11-08 1999-11-08
US18549500P true 2000-02-28 2000-02-28
US09/708,186 US6959708B1 (en) 1999-11-08 2000-11-07 Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina and other ailments
US11/192,852 US20060076011A1 (en) 1999-11-08 2005-07-29 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US11/340,410 US20060172017A1 (en) 1999-11-08 2006-01-25 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/340,410 US20060172017A1 (en) 1999-11-08 2006-01-25 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US12/708,407 US8096968B2 (en) 1999-11-08 2010-02-18 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/192,852 Continuation-In-Part US20060076011A1 (en) 1999-11-08 2005-07-29 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/708,407 Continuation US8096968B2 (en) 1999-11-08 2010-02-18 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces

Publications (1)

Publication Number Publication Date
US20060172017A1 true US20060172017A1 (en) 2006-08-03

Family

ID=46323681

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/340,410 Abandoned US20060172017A1 (en) 1999-11-08 2006-01-25 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US12/708,407 Active US8096968B2 (en) 1999-11-08 2010-02-18 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/708,407 Active US8096968B2 (en) 1999-11-08 2010-02-18 Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces

Country Status (1)

Country Link
US (2) US20060172017A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060237003A1 (en) * 1999-07-12 2006-10-26 Capnia, Incorporated Methods for treating headaches
US20100104665A1 (en) * 1999-11-08 2010-04-29 Capnia, Inc. Methods and Apparatus for Treating Rhinitis
US20100210565A1 (en) * 1999-11-08 2010-08-19 Rasor Julia S Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US8096968B2 (en) 1999-11-08 2012-01-17 Capnia, Inc. Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US9272036B2 (en) 2012-04-18 2016-03-01 Clover Hill Healthcare, Inc. Carbon dioxide, saline and additional active nasal delivery methods and treatments
US9370632B2 (en) 2012-06-04 2016-06-21 Clover Hill Healthcare, Inc. Nasal treatment delivery device for mixed carbon dioxide and saline
US10034857B2 (en) 2015-07-02 2018-07-31 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
US10052464B2 (en) 2012-06-04 2018-08-21 Clover Hill Healthcare, Inc. Low flow rate nasal treatment delivery device for mixed carbon dioxide and saline

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110301569A1 (en) * 2001-01-20 2011-12-08 Gordon Wayne Dyer Methods and apparatus for the CVCS
US20110056493A1 (en) * 2009-09-10 2011-03-10 Kim Iola Miller Sleep apnea vapor inhaler adapter

Citations (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1288850A (en) * 1918-01-12 1918-12-24 Harvey E Easly Oxygen-inhaling device.
US1449047A (en) * 1922-04-01 1923-03-20 Johnson Godwin Harry Pocket inhalation apparatus
US1742605A (en) * 1925-03-28 1930-01-07 Lemoine Renee Marie-Louise Perfume sprayer
US2574028A (en) * 1949-08-16 1951-11-06 Abbott Lab Gas container and dispensing means
US2585254A (en) * 1949-02-21 1952-02-12 Knapp Monarch Co Spraying device
US2651303A (en) * 1948-11-13 1953-09-08 Richard S Johnson Inhaler
US2860634A (en) * 1955-05-18 1958-11-18 Res Lab Inc Oxygen dispensing device and nose piece combination
US2920623A (en) * 1957-08-26 1960-01-12 Holt Jerome James Pocket oxygen dispenser
US3127058A (en) * 1964-03-31 Oxygen dispensing device
US3425414A (en) * 1965-05-28 1969-02-04 William J La Roche Inhalant dispenser
US3513843A (en) * 1967-07-05 1970-05-26 Gertrude Exler Respiratory device for rebreathing carbon dioxide
US3776227A (en) * 1972-01-31 1973-12-04 I Pitesky Portable hyperventilation relieving device
US3934585A (en) * 1970-08-13 1976-01-27 Maurice David M Method and apparatus for application of eye drops
US3974830A (en) * 1975-01-27 1976-08-17 Laverne Albert A Method and apparatus for carbon dioxide therapy (CDT) of addictons
US4067499A (en) * 1976-02-17 1978-01-10 Cohen Milton J Non-aerosol continuous spray dispenser
US4137914A (en) * 1975-12-12 1979-02-06 Aktiebolaget Draco Aerosol inhalation device
US4188946A (en) * 1977-10-07 1980-02-19 Rayburn Robert L Controllable partial rebreathing anesthesia circuit and respiratory assist device
US4273124A (en) * 1979-06-01 1981-06-16 Zimmerman J Earl Nasal cannula
US4447449A (en) * 1981-11-16 1984-05-08 The Upjohn Company Methods of treating ischemic states
US4465067A (en) * 1982-04-24 1984-08-14 Dragerwerk Aktiengesellschaft Oxygen insufflation device
US4554916A (en) * 1983-07-27 1985-11-26 James Watt Rotary proportioning inhalator
US4694850A (en) * 1985-10-11 1987-09-22 Nippon Tansan Gas Co., Ltd. Gas supply mechanism
US4934359A (en) * 1987-09-03 1990-06-19 Hal Blaine Nasal exhaler and method
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
US5123442A (en) * 1991-04-30 1992-06-23 Circle Seal Controls, Inc. Regulating shut off valve
US5262180A (en) * 1991-04-15 1993-11-16 University Of North Carolina At Chapel Hill Method for treating acute alkali exposure with carbon dioxide
US5318015A (en) * 1992-09-03 1994-06-07 Sven Mansson Inhaler having ejector structure that provides primary and secondary atomization of an actuated dose of medicament
US5370862A (en) * 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
US5431155A (en) * 1992-06-03 1995-07-11 Elettro Plastica S.P.A. Single-dose nasal dispenser for atomized liquid drugs
US5485827A (en) * 1990-12-05 1996-01-23 The General Hospital Corporation Methods and devices for treating plumonary vasoconstriction and asthma
US5490498A (en) * 1991-05-03 1996-02-13 Alliance Pharmaceutical Corp. Partial liquid breathing of fluorocarbons
US5559083A (en) * 1994-04-04 1996-09-24 Takeda Chemical Industries, Ltd. Composition comprising an isothiazolone compound
US5562644A (en) * 1995-03-01 1996-10-08 Mcleod; Martha S. Method and apparatus for the relief of headache pain
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5807357A (en) * 1997-08-19 1998-09-15 Kang; Meng-Che Compact nebulizer for treating the eyes
US5839433A (en) * 1993-10-12 1998-11-24 Higenbottam; Timothy William Nitric oxide treatment
US5851544A (en) * 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5918596A (en) * 1997-04-22 1999-07-06 Instrumentarium Corp. Special gas dose delivery apparatus for respiration equipment
US5938590A (en) * 1998-05-18 1999-08-17 Elliott; Peter Christopher Otoscope retrofit kit to allow multipurpose use
US5941241A (en) * 1997-05-12 1999-08-24 Weinstein; Robert E. Method and device for organizing and coordinating the combined use of topical aerosols for the treatment of respiratory disorders
US5951538A (en) * 1997-08-07 1999-09-14 Ceramatec, Inc. Gas generating device for delivering beneficial agents to a body cavity
US5959708A (en) * 1996-06-21 1999-09-28 Hyundai Electronics Industries Co., Ltd. Liquid crystal display having a conductive high molecular film for preventing the fringe field in the in-plane switching mode
US5983891A (en) * 1996-11-18 1999-11-16 Medlis Corp. Artificial ventilation methods for controlling carbon dioxide rebreathing
US5993428A (en) * 1996-10-05 1999-11-30 Hardge; Lawrence Head cover with eye spraying capability
US6001332A (en) * 1995-02-16 1999-12-14 The Boc Group Plc Medical gas mixture
US6125844A (en) * 1998-04-30 2000-10-03 Westwood Biomedical Portable oxygen based drug delivery system
US6258032B1 (en) * 1997-01-29 2001-07-10 William M. Hammesfahr Method of diagnosis and treatment and related compositions and apparatus
US6581539B1 (en) * 1999-08-16 2003-06-24 Ned S. Rasor Package and holder for dispenser
US6652479B2 (en) * 2000-02-28 2003-11-25 Capnia, Inc. Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments
US7017573B1 (en) * 1999-07-12 2006-03-28 Capnia, Incorporated Methods and apparatus for relieving headaches, rhinitis and other common ailments

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB408856A (en) 1933-08-14 1934-04-19 Wietske Van Seters Bosch Improvements in and relating to inhalers
CH247873A (en) 1945-02-06 1947-03-31 Albert Bischoff Anton Means for introducing medicinal substances and odorous substances in the nostrils.
DE837158C (en) 1949-06-10 1952-04-21 Draegerwerk Ag Anesthetic Machine
DE1491660A1 (en) 1966-11-15 1969-08-28 Oswald Brunn Miniair-Kleinsauerstoff- and Filterbeatmungsgeraet with different combinations
DE2323682B2 (en) 1973-05-10 1975-09-11 Hans-Joachim Dr.Med. 2000 Hamburg Lindemann
US4175704A (en) 1976-02-17 1979-11-27 Cohen Milton J Non-aerosol continuous spray dispenser
US4375812A (en) 1981-02-26 1983-03-08 Vaseen Vesper A Burn treatment by patient immersion in an inert, isotonic liquid, which has had ozone absorbed therein
EP0198708B1 (en) 1985-04-15 1991-06-12 Nippon Tansan Gas Co., Ltd. Portable oxygen inhaler
DE8906590U1 (en) 1989-05-30 1989-10-12 Oxicur-Medizin-Technik Vertriebsgesellschaft Mbh, 8401 Alteglofsheim, De
AT145563T (en) 1989-12-14 1996-12-15 Elof Eriksson Treatment system for wounds and other errors
FR2656218A1 (en) 1989-12-21 1991-06-28 France Prod Oxygenes Co Device for local treatment of the human or animal body using gas
DK0592540T3 (en) 1991-07-02 2000-06-26 Inhale Inc Method and device for delivering aerosolized medications
US5288462A (en) 1992-05-18 1994-02-22 Stephen D. Carter Sterilization apparatus and method
DE4319612A1 (en) 1993-06-14 1994-12-15 Frank Dipl Ing Beyer Arrangement for metering CO2 gas for subcutaneous injection for therapeutic purposes
US5558083A (en) 1993-11-22 1996-09-24 Ohmeda Inc. Nitric oxide delivery system
GB9404248D0 (en) 1994-03-05 1994-04-20 Boots Co Plc Pharmaceutical formulations
WO1998038944A1 (en) 1997-03-05 1998-09-11 Board Of Regents, The University Of Texas System Self-sealed irrigation system
US5525130A (en) 1995-02-08 1996-06-11 Board Of Trustees Operating Michigan State University Plant development affecting device and method
JPH08224321A (en) 1995-02-22 1996-09-03 Nippon Sanso Kk Oxygen can containing carbon dioxide
JPH0984876A (en) 1995-09-20 1997-03-31 Daido Hoxan Inc Gas mixing apparatus for carbon dioxide inhalation therapy
JP3317827B2 (en) 1995-10-09 2002-08-26 有限会社ドット Doser
DE19548652C2 (en) 1995-12-15 1999-12-30 Helga Steinfatt Handset to generate refrigeration for the therapy in medicine and cosmetics
AUPN976496A0 (en) 1996-05-10 1996-05-30 Glaxo Wellcome Australia Ltd Unit dose dispensing device
US5848998A (en) 1996-07-11 1998-12-15 Marasco, Jr.; Patrick V. Tissue debriding apparatus
SE9704261L (en) 1997-11-20 1999-05-21 Cardia Innovation Ab Method and apparatus for creating a substantially air-free atmosphere in an area
US6113922A (en) 1998-11-13 2000-09-05 Swenson; Russell H. Compositions expressing a pressure of carbon dioxide for improved healing of wounds
CN1736502A (en) 1999-03-03 2006-02-22 奥普蒂诺斯公司 Nasal delivery method
AT269056T (en) 1999-03-26 2004-07-15 Pozen Inc Highly effective dihydroergotaminhaltige pharmaceutical compositions
US20060172017A1 (en) 1999-11-08 2006-08-03 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
AU779413B2 (en) 1999-11-08 2005-01-20 Capnia Incorporated Method for co-application of gases and drugs to potentiate their action in relieving headaches, angina, and other ailments
US20070039615A1 (en) 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7014630B2 (en) 2003-06-18 2006-03-21 Oxyband Technologies, Inc. Tissue dressing having gas reservoir
US20060251542A1 (en) 2005-05-05 2006-11-09 Marc Sims Method for sterilizing articles using carbonated water
US20080169047A1 (en) 2007-01-17 2008-07-17 Capnia, Incorporated Hand-held, low-flow therapeutic gas dispensers

Patent Citations (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3127058A (en) * 1964-03-31 Oxygen dispensing device
US1288850A (en) * 1918-01-12 1918-12-24 Harvey E Easly Oxygen-inhaling device.
US1449047A (en) * 1922-04-01 1923-03-20 Johnson Godwin Harry Pocket inhalation apparatus
US1742605A (en) * 1925-03-28 1930-01-07 Lemoine Renee Marie-Louise Perfume sprayer
US2651303A (en) * 1948-11-13 1953-09-08 Richard S Johnson Inhaler
US2585254A (en) * 1949-02-21 1952-02-12 Knapp Monarch Co Spraying device
US2574028A (en) * 1949-08-16 1951-11-06 Abbott Lab Gas container and dispensing means
US2860634A (en) * 1955-05-18 1958-11-18 Res Lab Inc Oxygen dispensing device and nose piece combination
US2920623A (en) * 1957-08-26 1960-01-12 Holt Jerome James Pocket oxygen dispenser
US3425414A (en) * 1965-05-28 1969-02-04 William J La Roche Inhalant dispenser
US3513843A (en) * 1967-07-05 1970-05-26 Gertrude Exler Respiratory device for rebreathing carbon dioxide
US3934585A (en) * 1970-08-13 1976-01-27 Maurice David M Method and apparatus for application of eye drops
US3776227A (en) * 1972-01-31 1973-12-04 I Pitesky Portable hyperventilation relieving device
US3974830A (en) * 1975-01-27 1976-08-17 Laverne Albert A Method and apparatus for carbon dioxide therapy (CDT) of addictons
US4137914A (en) * 1975-12-12 1979-02-06 Aktiebolaget Draco Aerosol inhalation device
US4067499A (en) * 1976-02-17 1978-01-10 Cohen Milton J Non-aerosol continuous spray dispenser
US4188946A (en) * 1977-10-07 1980-02-19 Rayburn Robert L Controllable partial rebreathing anesthesia circuit and respiratory assist device
US4273124A (en) * 1979-06-01 1981-06-16 Zimmerman J Earl Nasal cannula
US4447449A (en) * 1981-11-16 1984-05-08 The Upjohn Company Methods of treating ischemic states
US4465067A (en) * 1982-04-24 1984-08-14 Dragerwerk Aktiengesellschaft Oxygen insufflation device
US4554916A (en) * 1983-07-27 1985-11-26 James Watt Rotary proportioning inhalator
US4694850A (en) * 1985-10-11 1987-09-22 Nippon Tansan Gas Co., Ltd. Gas supply mechanism
US4934359A (en) * 1987-09-03 1990-06-19 Hal Blaine Nasal exhaler and method
US5370862A (en) * 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
US5570683A (en) * 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5485827A (en) * 1990-12-05 1996-01-23 The General Hospital Corporation Methods and devices for treating plumonary vasoconstriction and asthma
US5262180A (en) * 1991-04-15 1993-11-16 University Of North Carolina At Chapel Hill Method for treating acute alkali exposure with carbon dioxide
US5123442A (en) * 1991-04-30 1992-06-23 Circle Seal Controls, Inc. Regulating shut off valve
US5490498A (en) * 1991-05-03 1996-02-13 Alliance Pharmaceutical Corp. Partial liquid breathing of fluorocarbons
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
US5431155A (en) * 1992-06-03 1995-07-11 Elettro Plastica S.P.A. Single-dose nasal dispenser for atomized liquid drugs
US5318015A (en) * 1992-09-03 1994-06-07 Sven Mansson Inhaler having ejector structure that provides primary and secondary atomization of an actuated dose of medicament
US5839433A (en) * 1993-10-12 1998-11-24 Higenbottam; Timothy William Nitric oxide treatment
US5559083A (en) * 1994-04-04 1996-09-24 Takeda Chemical Industries, Ltd. Composition comprising an isothiazolone compound
US6001332A (en) * 1995-02-16 1999-12-14 The Boc Group Plc Medical gas mixture
US5562644A (en) * 1995-03-01 1996-10-08 Mcleod; Martha S. Method and apparatus for the relief of headache pain
US5908870A (en) * 1995-03-01 1999-06-01 Martha Sue McLeod Method and apparatus for the relief of headache pain
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5959708A (en) * 1996-06-21 1999-09-28 Hyundai Electronics Industries Co., Ltd. Liquid crystal display having a conductive high molecular film for preventing the fringe field in the in-plane switching mode
US5993428A (en) * 1996-10-05 1999-11-30 Hardge; Lawrence Head cover with eye spraying capability
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5983891A (en) * 1996-11-18 1999-11-16 Medlis Corp. Artificial ventilation methods for controlling carbon dioxide rebreathing
US6258032B1 (en) * 1997-01-29 2001-07-10 William M. Hammesfahr Method of diagnosis and treatment and related compositions and apparatus
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5918596A (en) * 1997-04-22 1999-07-06 Instrumentarium Corp. Special gas dose delivery apparatus for respiration equipment
US5941241A (en) * 1997-05-12 1999-08-24 Weinstein; Robert E. Method and device for organizing and coordinating the combined use of topical aerosols for the treatment of respiratory disorders
US5951538A (en) * 1997-08-07 1999-09-14 Ceramatec, Inc. Gas generating device for delivering beneficial agents to a body cavity
US5807357A (en) * 1997-08-19 1998-09-15 Kang; Meng-Che Compact nebulizer for treating the eyes
US5851544A (en) * 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US6125844A (en) * 1998-04-30 2000-10-03 Westwood Biomedical Portable oxygen based drug delivery system
US5938590A (en) * 1998-05-18 1999-08-17 Elliott; Peter Christopher Otoscope retrofit kit to allow multipurpose use
US7017573B1 (en) * 1999-07-12 2006-03-28 Capnia, Incorporated Methods and apparatus for relieving headaches, rhinitis and other common ailments
US6581539B1 (en) * 1999-08-16 2003-06-24 Ned S. Rasor Package and holder for dispenser
US6652479B2 (en) * 2000-02-28 2003-11-25 Capnia, Inc. Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments
US20050228337A1 (en) * 2000-02-28 2005-10-13 Capnia, Incorporated Transcutaneous infusion of carbon dioxide for local relief of pain and other ailments

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110040240A1 (en) * 1999-07-12 2011-02-17 Capnia, Inc. Methods for treating rhinitis and conjunctivitis
US20060237004A1 (en) * 1999-07-12 2006-10-26 Capnia, Incorporated Methods for treating trigeminal neuralgia
US20060243276A1 (en) * 1999-07-12 2006-11-02 Capnia, Incorporated Methods for treating rhinitis and conjunctivitis
US20070017508A1 (en) * 1999-07-12 2007-01-25 Capnia, Incorporated Methods for treating jaw pain
US8763604B2 (en) 1999-07-12 2014-07-01 Capnia, Inc. Methods for treating allergy
US8464711B2 (en) 1999-07-12 2013-06-18 Capnia, Inc. Methods for treating headaches
US7827986B2 (en) 1999-07-12 2010-11-09 Capnia, Inc. Methods for treating jaw pain
US7836883B2 (en) 1999-07-12 2010-11-23 Capnia, Inc. Methods for treating rhinitis and conjunctivitis
US7845348B2 (en) 1999-07-12 2010-12-07 Capnia, Inc. Methods for treating trigeminal neuralgia
US7845347B2 (en) 1999-07-12 2010-12-07 Capnia, Inc. Methods for treating headaches
US20060237003A1 (en) * 1999-07-12 2006-10-26 Capnia, Incorporated Methods for treating headaches
US8096968B2 (en) 1999-11-08 2012-01-17 Capnia, Inc. Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US8398580B2 (en) 1999-11-08 2013-03-19 Capnia, Inc. Methods and apparatus for treating rhinitis
US20100210565A1 (en) * 1999-11-08 2010-08-19 Rasor Julia S Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US20100104665A1 (en) * 1999-11-08 2010-04-29 Capnia, Inc. Methods and Apparatus for Treating Rhinitis
US9272036B2 (en) 2012-04-18 2016-03-01 Clover Hill Healthcare, Inc. Carbon dioxide, saline and additional active nasal delivery methods and treatments
US9370632B2 (en) 2012-06-04 2016-06-21 Clover Hill Healthcare, Inc. Nasal treatment delivery device for mixed carbon dioxide and saline
US10052464B2 (en) 2012-06-04 2018-08-21 Clover Hill Healthcare, Inc. Low flow rate nasal treatment delivery device for mixed carbon dioxide and saline
US10034857B2 (en) 2015-07-02 2018-07-31 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery

Also Published As

Publication number Publication date
US8096968B2 (en) 2012-01-17
US20100152120A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
FI110922B (en) Nitrogen oxides from the air for medical applications
ES2389297T3 (en) Apparatus for administering intermittent percussive ventilation and breathing head assembly unit for use therein
US5656255A (en) Composition to help stop smoking
EP1158992B1 (en) Use of xenon for preparing a pharmaceutical preparation for treating neurointoxications
US7013894B2 (en) Portable, handheld, pneumatic driven medicinal nebulizer
KR100414699B1 (en) Dinucleotide useful in treating lung disease
US6601580B1 (en) Enhancing therapeutic effectiveness of nitric oxide inhalation
KR100371082B1 (en) Treatment of asthma and pulmonary vasoconstriction
AU2003243074B2 (en) A buffered, liquid nicotine composition for pulmonary administration
JP3911290B2 (en) Prescription for anesthesia, including aerosol
US20150283366A1 (en) Transdermal drug delivery method and system
US7191776B2 (en) Nebulizer breathing system
US20050028812A1 (en) Nasal delivery device
US20150320963A1 (en) Intermittent dosing of nitric oxide gas
JP2704019B2 (en) Drug-containing matrix
US20080066741A1 (en) Methods and systems of delivering medication via inhalation
EP1927373B1 (en) Inhalation nebulizer
US5457100A (en) Method for treatment of recurrent paroxysmal neuropsychiatric
ES2280343T3 (en) pharmaceutical compositions containing cannabis.
US8001963B2 (en) Integrated nebulizer and particle dispersion chamber for nasal delivery of medicament to deep nasal cavity and paranasal sinuses
US6874507B2 (en) System for effecting smoking cessation
ES2284226T3 (en) Device for delivering aerosolized medication.
JP4195191B2 (en) Administration of aerosolized active agent
DE60030870T2 (en) suffering arrangement for treatment of headache, rhinitis and other
US5687746A (en) Dry powder delivery system

Legal Events

Date Code Title Description
AS Assignment

Owner name: CAPNIA, INCORPORATED, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RASOR, JULIA S.;RASOR, NED S.;PEREIRA, GERARD F.;REEL/FRAME:017445/0036;SIGNING DATES FROM 20060324 TO 20060404

AS Assignment

Owner name: CAPNIA, INC.,CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME AND TO UPDATE THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 017445 FRAME 0036. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE NAME IS CAPNIA, INC. AND THE ASSIGNEE ADDRESS IS 2445 FABER PLACE, SUITE 250, PALO ALTO, CA 94303;ASSIGNORS:RASOR, JULIA S.;RASOR, NED S.;PEREIRA, GERARD F.;SIGNING DATES FROM 20060324 TO 20060404;REEL/FRAME:024412/0204